Compass Pathways Touts Phase 3 COMP360 Depression Data, Eyes Rolling NDA and 2026 Launch Readiness

Key Points

• COMP360 Phase 3 data showed a "highly statistically significant" and clinically meaningful antidepressant effect for the 25mg dose with onset by day two and durability out to at least 26 weeks (25% response in COMP005; ~40% response at six weeks in the second study), and the treatment was generally well tolerated with transient dosing-day adverse effects and no DSMB signals of suicidality.
• Compass has aligned with regulators on a potential rolling NDA, expects to add the second study's 26-week data in early Q3 and complete the submission in the back half of the year, and says breakthrough designation could enable priority review as it aims to be commercially ready by year-end.
• Commercial plans target existing SPRAVATO-equipped clinics to accelerate uptake, with CPT administration codes now live, a buy-and-bill strategy, training grants for providers, and DEA/state rescheduling identified as a key near-term launch variable.

Compass Pathways NASDAQ: CMPS executives outlined the company’s latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami Fadia.

Phase 3 results highlighted rapid and durable antidepressant effects

CEO Kabir Nath said the company is “potentially closest to a regulatory approval for a classic psychedelic,” emphasizing that Compass is running a Phase 3 program evaluating COMP360, its proprietary synthetic psilocybin, in treatment-resistant depression (TRD).

Nath recapped data the company released in February, including primary endpoint results from two Phase 3 studies and 26-week blinded follow-up data from the first study. In both Phase 3 studies, Nath said Compass observed a “highly statistically significant” difference in change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) for the 25mg dose, compared with placebo in one study and 1mg in the other. He described the difference as “clinically meaningful.”

In the first Phase 3 study (COMP005), Nath said 25% of patients achieved a clinically meaningful response, which he defined as “a more than 25% reduction in MADRS.” He also emphasized the speed and durability of effect, saying the company sees onset by the beginning of day two and durability “out to at least 26 weeks” from one dose or a second dose delivered “somewhere in around week 10.”

For the second Phase 3 study, Nath said the company has only six-week primary endpoint data so far and observed 40% of patients achieving that clinically meaningful response with a second fixed dose. He said the company is looking forward to the 26-week data from the second study to assess durability and whether a potential third dose could extend it further.

Safety and DSMB monitoring

Nath said COMP360 has been “well-tolerated,” with transient adverse effects on dosing day such as headache, nausea, and fatigue, which he said were “overwhelmingly resolved within 24 or at worst 48 hours.”

He added that an independent data safety monitoring board (DSMB), which monitored both studies, stated that across the data reviewed to date it had seen “no clinically concerning imbalances around suicidality or suicidal ideation.”

Regulatory path and timing of submission

Nath said Compass has had breakthrough therapy designation for TRD for “some eight years” and has been in active dialogue with regulators. He said the company has aligned “in principle” with the agency on the potential for a rolling new drug application (NDA) submission, and that process is underway.

According to Nath, Compass expects to complete the NDA submission with the 26-week data from the second Phase 3 study in early Q3, which he said will be the final item in the submission. He said the company expects to complete its submission in the “back part of this year,” and noted that breakthrough designation could support a priority review. Nath said Compass is not providing formal guidance on a PDUFA date, but said the company expects to be “ready commercially by the end of this year.”

Commercial strategy: leveraging ketamine clinic infrastructure

Discussion also focused on the go-to-market backdrop created by Johnson & Johnson’s SPRAVATO (esketamine), which is delivered under supervision in office-based settings. Chief Commercial Officer Lori Englebert said SPRAVATO’s footprint continues to expand, adding “about 500 sites a quarter” even “six, seven years past launch.” She said SPRAVATO continues to grow “about 50% year-over-year.”

Englebert argued that sites already set up for SPRAVATO are well positioned to adopt COMP360, saying a “SPRAVATO room is a COMP360 site and potentially a COMP360 room,” because the existing infrastructure supports multi-hour supervised treatments and REMS-related requirements.

Chief Patient Officer Steve Levine said SPRAVATO established important groundwork for “interventional pharmaceutical” delivery, including multidisciplinary care teams, multi-room operations, and experience onboarding new FDA-approved options for TRD. Levine contrasted the patient burden of SPRAVATO—which he described as “25-50 three-hour treatments” in a year for many patients—with COMP360’s emerging profile, which he said could provide rapid feedback on response and potentially durable benefit out to at least six months after one or two treatments.

Reimbursement, training, and launch readiness priorities

Levine said Compass began early efforts to establish a reimbursement framework and collaborated with others to apply for new CPT codes specific to psychedelic administration-day services. He said the codes are “approved” and “live,” designed to better capture team workload and practice expenses and to be billed on an hour-by-hour basis. He added that given COMP360 is expected to require “about six hours of observation,” the reimbursement should compare favorably with current economics for SPRAVATO rooms.

Englebert said Compass plans to support “buy and bill,” noting psychiatry is less accustomed to it than other fields but that SPRAVATO already uses buy and bill at sites. She estimated “30%-40%” of SPRAVATO volume goes through buy and bill, while also noting SPRAVATO prescribing is concentrated: of roughly 7,300 eligible sites, she said 80% of volume comes from fewer than 1,000 sites. On pricing, Englebert said the company is waiting for additional data from the second study to better understand dosing frequency before finalizing a price.

On site preparedness and patient experience, Englebert said Compass’ “North Star” is enabling a positive site and patient experience through education, support materials, and adequate staff training. She said the company will track readiness and adoption metrics including infrastructure and REMS readiness, training, prescriptions, prescribers, patient counts, and payer coverage. She also flagged post-approval controlled-substance rescheduling as a key near-term launch variable, noting DEA rescheduling typically occurs within a 90-day statutory window and that states must also reschedule to allow prescribing and shipment. Englebert said Compass is working to shorten the state-level timing and expects 25-30 states to enact immediately following DEA action, with others within about 30 days, while engaging in states with less-defined timelines.

On workforce training, Levine distinguished between education and operational training, noting Compass has already begun certain disease-state and data education through its medical science liaison team. He said many healthcare providers have already received foundational psychedelic training through existing organizations, and Compass plans to give credit for prior training. Levine also said Compass announced it would provide grants to training organizations to develop foundational and COMP360-specific materials, with the product-specific component intended to be limited in hours and cost after approval to avoid creating barriers to adoption.

Finally, executives said near-term uptake is expected to begin in high-capacity interventional psychiatry clinics, while longer-term access efforts include community behavioral health, hospital systems, integrated delivery networks (IDNs), and other care models. Levine said these settings may not individually be high-volume prescribers, but in aggregate could expand access by enabling treatment where patients already receive care.

About Compass Pathways NASDAQ: CMPS

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.